Search

Objective: In patients with a history of suicidal depression, recurrence of depressive symptoms can easily reactivate suicidal thinking. In this study, we investigated whether training in mindfulness, which is aimed at helping patients "decenter" from negative thinking, could help weaken the link between depressive symptoms and suicidal cognitions., Method: Analyses were based on data from a recent randomized controlled trial, in which previously suicidal patients were allocated to mindfulness-based cognitive therapy (MBCT), an active control treatment, cognitive psychoeducation (CPE), which did not include any meditation practice, or treatment as usual (TAU). After the end of the treatment phase, we compared the associations between depressive symptoms, as assessed through self-reports on the Beck Depression Inventory-II (Beck, Steer, & Brown, 1996), and suicidal thinking, as assessed through the Suicidal Cognitions Scale (Rudd et al., 2001)., Results: In patients with minimal to moderate symptoms at the time of assessment, comparisons of the correlations between depressive symptoms and suicidal cognitions showed significant differences between the groups. Although suicidal cognitions were significantly related to levels of symptoms in the 2 control groups, there was no such relation in the MBCT group., Conclusion: The findings suggest that, in patients with a history of suicidal depression, training in mindfulness can help to weaken the association between depressive symptoms and suicidal thinking, and thus reduce an important vulnerability for relapse to suicidal depression., ((c) 2015 APA, all rights reserved).)

Few empirical studies have explored the associations between formal and informal mindfulness home practice and outcome in Mindfulness-based Cognitive Therapy (MBCT). In this study ninety-nine participants randomised to MBCT in a multi-centre randomised controlled trial completed self-reported ratings of home practice over 7 treatment weeks. Recurrence of Major Depression was assessed immediately after treatment, and at 3, 6, 9, and 12-months post-treatment. Results identified a significant association between mean daily duration of formal home practice and outcome and additionally indicated that participants who reported that they engaged in formal home practice on at least 3 days a week during the treatment phase were almost half as likely to relapse as those who reported fewer days of formal practice. These associations were independent of the potentially confounding variable of participant-rated treatment plausibility. The current study identified no significant association between informal home practice and outcome, although this may relate to the inherent difficulties in quantifying informal home mindfulness practice. These findings have important implications for clinicians discussing mindfulness-based interventions with their participants, in particular in relation to MBCT, where the amount of participant engagement in home practice appears to have a significant positive impact on outcome., (Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Objective: We compared mindfulness-based cognitive therapy (MBCT) with both cognitive psychological education (CPE) and treatment as usual (TAU) in preventing relapse to major depressive disorder (MDD) in people currently in remission following at least 3 previous episodes., Method: A randomized controlled trial in which 274 participants were allocated in the ratio 2:2:1 to MBCT plus TAU, CPE plus TAU, and TAU alone, and data were analyzed for the 255 (93%; MBCT = 99, CPE = 103, TAU = 53) retained to follow-up. MBCT was delivered in accordance with its published manual, modified to address suicidal cognitions; CPE was modeled on MBCT, but without training in meditation. Both treatments were delivered through 8 weekly classes., Results: Allocated treatment had no significant effect on risk of relapse to MDD over 12 months follow-up, hazard ratio for MBCT vs. CPE = 0.88, 95% CI [0.58, 1.35]; for MBCT vs. TAU = 0.69, 95% CI [0.42, 1.12]. However, severity of childhood trauma affected relapse, hazard ratio for increase of 1 standard deviation = 1.26 (95% CI [1.05, 1.50]), and significantly interacted with allocated treatment. Among participants above median severity, the hazard ratio was 0.61, 95% CI [0.34, 1.09], for MBCT vs. CPE, and 0.43, 95% CI [0.22, 0.87], for MBCT vs. TAU. For those below median severity, there were no such differences between treatment groups., Conclusion: MBCT provided significant protection against relapse for participants with increased vulnerability due to history of childhood trauma, but showed no significant advantage in comparison to an active control treatment and usual care over the whole group of patients with recurrent depression.

A common sequella of chronic laminitis in horses is repeated abscesses with variable lameness and drainage. It is unclear whether the exudate represents the debridement phase of a non-septic inflammatory process involving clearance of laminar tissue damaged during the acute episode of laminitis, or a response to a microbial infection developed by ascent of microbes from the environment to the tissue via the white line. The objective of this study was to evaluate the possibility that an undiagnosed microbial infection in laminar tissue is present in laminar tissue collected from chronically laminitic horses without an active hoof abscess. Methods to collect laminar tissue, aseptically, from control (non-laminitic) horses and those with chronic/recurrent laminitis are described. Laminae homogenates were evaluated for the presence of bacteria. Bacteria were identified using biochemical tests and sequencing of 16S rRNA and virulence genes. Laminae from chronically laminitic horses revealed 100-fold higher levels (P=0.002) of bacteria compared to control, non-laminitic horses. Although environmental organisms were identified, potential pathogens were identified. Included were Gram positive bacteria, Brevibacterium luteolum, coagulase-negative Staphylococcus spp. as well as Gram negative bacteria, enterohemorrhagic Escherichia coli and Alcaligenes faecalis. Further research is warranted to evaluate the role of bacteria in equine chronic laminitis., (Copyright © 2012 Elsevier B.V. All rights reserved.)

There has been a groundswell of interest in the UK in Mindfulness-Based Stress Reduction (MBSR) and its derivatives, particularly Mindfulness-Based Cognitive Therapy (MBCT). Many health, education and social work practitioners have sought ways to develop their competencies as mindfulness-based teachers, and increasing numbers of organisations are developing mindfulness-based training programmes. However, the rapid expansion of interest in mindfulness-based approaches has meant that those people offering training for MBSR and MBCT teachers have had to consider some quite fundamental questions about training processes, standards and competence. They also need to consider how to develop a robust professional context for the next generation of mindfulness-based teachers. The ways in which competencies are addressed in the secular mainstream contexts in which MBSR and MBCT are taught are examined to enable a consideration of the particularities of mindfulness-based teaching competence. A framework suggesting how competencies develop in trainees is presented. The current status of methodologies for assessing competencies used in mindfulness-based training and research programmes is reviewed. We argue that the time is ripe to continue to develop these dialogues across the international community of mindfulness-based trainers and teachers.

Background: Depression is often a chronic relapsing condition, with relapse rates of 50-80% in those who have been depressed before. This is particularly problematic for those who become suicidal when depressed since habitual recurrence of suicidal thoughts increases likelihood of further acute suicidal episodes. Therefore the question how to prevent relapse is of particular urgency in this group., Methods/design: This trial compares Mindfulness-Based Cognitive Therapy (MBCT), a novel form of treatment combining mindfulness meditation and cognitive therapy for depression, with both Cognitive Psycho-Education (CPE), an equally plausible cognitive treatment but without meditation, and treatment as usual (TAU). It will test whether MBCT reduces the risk of relapse in recurrently depressed patients and the incidence of suicidal symptoms in those with a history of suicidality who do relapse. It recruits participants, screens them by telephone for main inclusion and exclusion criteria and, if they are eligible, invites them to a pre-treatment session to assess eligibility in more detail. This trial allocates eligible participants at random between MBCT and TAU, CPE and TAU, and TAU alone in a ratio of 2:2:1, stratified by presence of suicidal ideation or behaviour and current anti-depressant use. We aim to recruit sufficient participants to allow for retention of 300 following attrition. We deliver both active treatments in groups meeting for two hours every week for eight weeks. We shall estimate effects on rates of relapse and suicidal symptoms over 12 months following treatment and assess clinical status immediately after treatment, and three, six, nine and twelve months thereafter., Discussion: This will be the first trial of MBCT to investigate whether MCBT is effective in preventing relapse to depression when compared with a control psychological treatment of equal plausibility; and to explore the use of MBCT for the most severe recurrent depression--that in people who become suicidal when depressed.

Objectives: Thought suppression is a strategy aimed at mental control that may paradoxically increase the frequency of unwanted thoughts. This preliminary study examined effects of mindfulness-based cognitive therapy (MBCT) on thought suppression and depression in individuals with past depression and suicidality., Methods: In a randomized controlled trial design, 68 participants were allocated to an MBCT group or a treatment-as-usual waitlist control. Measures of thought suppression and depression were taken pre- and post-treatment., Results: MBCT did not reduce thought suppression as measured by the White Bear Suppression Inventory, but significantly reduced self-reported attempts to suppress in the previous week., Conclusions: Preliminary evidence suggests that MBCT for suicidality may reduce thought suppression, but differential effects on thought suppression measures warrant further studies.

Background: Bipolar disorder is highly recurrent and rates of comorbidity are high. Studies have pointed to anxiety comorbidity as one factor associated with risk of suicide attempts and poor overall outcome. This study aimed to explore the feasibility and potential benefits of a new psychological treatment (Mindfulness-based Cognitive Therapy: MBCT) for people with bipolar disorder focusing on between-episode anxiety and depressive symptoms., Methods: The study used data from a pilot randomized trial of MBCT for people with bipolar disorder in remission, focusing on between-episode anxiety and depressive symptoms. Immediate effects of MBCT versus waitlist on levels of anxiety and depression were compared between unipolar and bipolar participants., Results: The results suggest that MBCT led to improved immediate outcomes in terms of anxiety which were specific to the bipolar group. Both bipolar and unipolar participants allocated to MBCT showed reductions in residual depressive symptoms relative to those allocated to the waitlist condition., Limitations: Analyses were based on a small sample, limiting power. Additionally the study recruited participants with suicidal ideation or behaviour so the findings cannot immediately be generalized to individuals without these symptoms., Conclusions: The study, although preliminary, suggests an immediate effect of MBCT on anxiety and depressive symptoms among bipolar participants with suicidal ideation or behaviour, and indicates that further research into the use of MBCT with bipolar patients may be warranted.

Suicide is a significant world health problem, with more deaths by suicide globally than by war. We need to better understand the cognitive processes underlying suicidal thinking for improved treatment development. Cognitive psychology indicates that mental imagery can be causal in determining future behavior, yet the occurrence of suicide-related imagery has not previously been investigated. Interviews with 15 depressed and formerly suicidal patients in remission found that all patients reported experiencing detailed mental imagery in addition to verbal thoughts when at their most despairing, for example images of making a future suicide attempt. A clinical measure of the severity of suicidal ideation was associated with both preoccupation with suicide-related imagery and perceived imagery realness. Echoing flashbacks in posttraumatic stress disorder, the current images appeared like "flash-forwards" to suicide. These results provide the first data to our knowledge on the existence of mental imagery in suicidality, opening a promising new avenue for research.

This study investigated the effects of a meditation-based treatment for preventing relapse to depression, mindfulness-based cognitive therapy (MBCT), on prefrontal alpha-asymmetry in resting electroencephalogram (EEG), a biological indicator of affective style. Twenty-two individuals with a previous history of suicidal depression were randomly assigned to either MBCT (N=10) or treatment-as-usual (TAU, N=12). Resting electroencephalogram was measured before and after an 8-week course of treatment. The TAU group showed a significant deterioration toward decreased relative left-frontal activation, indexing decreases in positive affective style, while there was no significant change in the MBCT group. The findings suggest that MBCT can help individuals at high risk for suicidal depression to retain a balanced pattern of baseline emotion-related brain activation.

Once suicidal thoughts have emerged as a feature of depression they are likely to be reactivated as part of a suicidal mode of mind whenever sad mood reappears. This article reviews the methods and the usefulness of mindfulness-based cognitive therapy (MBCT) as a treatment for the prevention of the reactivation of the suicidal mode. MBCT integrates mindfulness meditation practices and cognitive therapy techniques. It teaches participants to develop moment-by-moment awareness, approaching ongoing experience with an attitude of nonjudgment and acceptance. Participants are increasingly able to see their thoughts as mental events rather than facts (metacognitive awareness). A case example illustrates how mindfulness skills develop with MBCT and how they relate to the cognitive processes that fuel suicidal crises. An ongoing controlled trial will provide further evidence, but pilot work suggests that MBCT is a promising intervention for those who have experienced suicidal ideation in the past., ((c) 2005 Wiley Periodicals, Inc.)

Negative biases in processing information about the self have long been recognised as a central feature in the development and maintenance of clinical depression. In practice, however, it may not be easy to distinguish between patients whose negative thinking about the self is primarily an aspect of current mood state, and those for whom it represents a reflection of more enduring issues (low self-esteem). The paper speculates that, in both cases, metacognitive awareness (acceptance of the idea that thoughts, assumptions and beliefs are mental events and processes rather than reflections of objective truth) may be an important precursor to active engagement in therapy on the part of the patient, and considers what aspects of cognitive therapy might be used to promote it in clinical practice.

ICI 176,334 is a nonsteroidal anti-androgen that has been shown to selectively block peripheral androgen receptors in rats and is presumed to do so in chickens. In chickens, androgens stimulate secondary sexual characteristics (e.g., comb), but inhibit growth and the immune tissues. The present study examined the effect of dietary ICI 176,334 (5 or 25 mg/kg body weight) on growth in chickens in the presence or absence of testosterone treatment (as 1-cm long silastic implants). Treatments began at 2 wk of age and continued through 6 wk of age. Testosterone alone reduced body growth (average daily gain and shank-toe length, together with weights of the body, skeletal muscle, and the bursa of Fabricius, an immune tissue), and stimulated comb development. At the low dose (5 mg/kg), ICI 176,334 alone had no effect on body growth or organ weight with the exception that comb weight was reduced. At the high dose (25 mg/kg), ICI 176,334 decreased growth (body weight, average daily gain, and shank-toe length) and organ weights (breast muscle, bursa of Fabricius, testis, and comb weights). This effect may represent a toxicity. As might be expected with an anti-androgen, ICI 176,334 (at either 5 or 25 mg/kg) completely suppressed the stimulation of comb growth evoked by testosterone. Similarly, ICI 176,334 (5 mg/kg) overcame, albeit partially, the growth-suppressive effects of testosterone (on body weight, average daily gain, shank-toe length, and breast muscle weight) and also had inhibitory effects on the weights of the testis and bursa of Fabricius. The anti-androgen, ICI 176,334, did not influence the reduction in circulating concentrations of luteinizing hormone occurring after testosterone treatment. The present data are consistent with the growth-suppressive effects of testosterone in chickens being mediated via a peripheral androgen receptor. No effects of either testosterone or ICI 176,334 were observed on circulating concentrations of insulin-like growth factor-I despite the marked changes in growth rate.

The present studies examined the effect of three androgens, testosterone, a reduced form 5 alpha-dihydrotestosterone (5 alpha-DHT), and the readily aromatizable anabolic androgen, 19-nortestosterone, on growth in male and female turkeys. Growth (body weight, average daily gain, and right breast muscle weight) was increased by testosterone (females), 5 alpha-DHT (males and females), and 19-nortestosterone (males and females). Moreover, both feed:gain ratio and the weight of abdominal adipose tissue was reduced in turkeys treated with testosterone (females), 5 alpha-DHT (males and females), and 19-nortestosterone (females and males). Bursa of Fabricius weights were reduced in androgen-treated male or female turkeys with the decrease following 19-nortestosterone being greater than those observed with either testosterone or 5 alpha-DHT. Androgen treatment had no effect on skeletal growth (as indicated by shank-toe length) or weights of the liver, spleen, or testes. In female turkeys, plasma concentrations of hormones were determined following androgen treatment. No effects were observed on plasma concentrations of insulin-like growth factor-I or luteinizing hormone after any androgen treatment. Testosterone administration was followed by a physiological increase in the plasma concentrations of testosterone. Plasma concentrations of growth hormone were unaffected by either 5 alpha-DHT or 19-nortestosterone but reduced by the high dose of testosterone. The effect of castration on growth in the presence or absence of 19-nortestosterone was also examined. Castration did not depress growth compared with sham-operated controls, but increased adiposity. 19-Nortestosterone increased growth of castrated turkeys, increased muscle weight, and reduced abdominal adipose tissue weight.

The growth response of poultry to androgens is ambiguous, with both increases and decreases being reported. This may reflect the use of pharmacological doses. The present study examined the effect of physiological concentrations of androgens on growth of intact male, intact female, and castrated chickens. Physiological concentrations of androgen were attained by subcutaneous silastic implants. In mammals, androgens have both androgenic effects on the reproductive organs and anabolic growth-promoting effects on body and muscle growth. Some androgens, for instance 5 alpha-dihydrotestosterone (5 alpha-DHT) have high androgenic activity (5 alpha-DHT greater than testosterone) but others, e.g., 19-nortestosterone, have high anabolic activities (19-nortestosterone greater than testosterone greater than 5 alpha-DHT). The relative effects of testosterone, 5 alpha-DHT, and 19-nortestosterone on growth were compared in chickens. In young, intact male and female chicks, growth was suppressed by 1.0-cm silastic implants of testosterone and 5 alpha-DHT (5 alpha-DHT greater than testosterone). Castrated chicks were implanted with implants of various sizes (.3, 1.0, and 3.0 cm) containing testosterone, 5 alpha-DHT, or 19-nortestosterone. The androgens inhibited body weight gain: 19-nortestosterone reducing body weight at all three doses, 5 alpha-DHT reducing body weight at the intermediate and high doses, and testosterone tending to reduce body weight only at the high dose. Testosterone (3.0 cm), 5 alpha-DHT (all doses), and 19-nortestosterone (all doses) reduces skeletal growth, as indicated by shank-toe length. In contrast to their growth-suppressing effect, all three steroids exerted an androgenic effect; stimulating comb and wattle development (19-nortestosterone greater than 5 alpha-DHT greater than testosterone). It is concluded that androgens are androgenic but are not anabolic in chickens.

Castrated chicks implanted with testosterone or 5 alpha-dihydrotestosterone (5 alpha-DHT) had circulating concentrations of the respective androgen similar to or less than in sham-operated chicks. In castrated chicks, 5 alpha-DHT or 19-nortestosterone (19-NorT) inhibited growth as indicated by body weight, while testosterone and 5 beta-dihydrotestosterone (5 beta-DHT) were without effect. In intact male or female chicks, growth was inhibited by either testosterone or 5 alpha-DHT but was unaffected by 5 beta-DHT or estradiol-17 beta. Plasma concentrations of luteinizing hormone (LH) were reduced in castrated chicks receiving implants of either testosterone or 19-NorT. Only the highest dose of 5 alpha-DHT depressed the circulating concentration of LH; lower doses of 5 alpha-DHT being without effect. During the first 6 weeks of growth, plasma concentrations of GH were unaffected by most steroid treatments (5 alpha-DHT, 5 beta-DHT, low doses of testosterone, estradiol-17 beta) in castrated or in intact male or in female chicks. Similarly, 19-NorT did not affect plasma concentrations of GH in castrated chicks. The high dose of testosterone, however, depressed plasma concentrations of GH in castrated chicks between 2 and 6 weeks of age. Between 8 and 12 weeks of age, all steroids tested, except 5 alpha-DHT, were without effect on plasma concentrations of GH. Plasma concentrations of GH were increased in 5 alpha-DHT-treated chickens. This effect was observed irrespective of dose of 5 alpha-DHT or whether the androgen was administered to castrated or to intact male or to female chicks.

Beck's cognitive model of depression suggests that negative cognitions can maintain depression. Thus reducing the frequency of negative cognitions should reduce depression. Consistent with this proposition, in low endogenous patients with primary major depressive disorder, distraction produced fewer depressing thoughts than the control procedure, with corresponding differences in self-report and psychomotor measures.

The effect of orchiectomy and androgen replacement on cockerel adrenocortical function was investigated. Orchiectomized cockerels (2 weeks old) were implanted with Silastic tubing containing various amounts of one of the following steroids: cholesterol, testosterone (T), androstenedione (A4), and 5 alpha-dihydrotestosterone (DHT). Birds were administered additional implants, containing doses of steroids equivalent to those of the initial implants, at 4 and 8 weeks of treatment (i.e., 6 and 10 weeks of age). Sham-operated cockerels administered empty implants served as intact controls for comparison of data. Animals were killed after 10 weeks of treatment (12 weeks old). Trunk plasma corticosterone (B) and plasma T, and B production by collagenase-isolated adrenocortical cells incubated briefly (2 hr) with or without steroidogenic agents were measured by radioimmunoassay. Orchiectomy with implantation of the inert sterol, cholesterol (hereafter referred to as orchiectomy), did not alter plasma B concentrations and did not affect basal cellular B production or cellular B production induced by a maximal steroidogenic concentration of ACTH or that maximally supported by 25-hydroxycholesterol. However, orchiectomy did lower maximal 8-bromo-cyclic AMP-induced B production by 30%. Low-implant doses of A4 (1-cm implant) and T (0.3-cm implant), that maintained comb growth, lowered plasma B concentrations by 24-42%, whereas a high-implant dose of T (3-cm implant) and all implant doses of DHT had no effect on plasma B concentrations. Thus, androgen replacement had different effects on plasma B depending on the type of androgen and the implant dose. In contrast, androgen replacement consistently suppressed basal and maximal ACTH-induced cellular B production regardless of the type of androgen. Furthermore, the degree of suppression was dose-dependent. These results suggest that the differential effect of androgen replacement on plasma B concentrations was due to differences in the clearance of circulating B and/or differences in blood volume. In addition, the present study suggests that in the absence of the testes, androgens are suppressants of adrenocortical cell function in the domestic fowl.

With the development of cognitive models of depression, interest in identifying an enduring cognitive style characteristic of depression-prone individuals has increased. However, empirical evidence for cognitive vulnerability of this kind is as yet sparse. The paper describes the development of a Cognitions Questionnaire (CQ), designed not only to provide an overall measure of depressive cognitive style, but also to assess specific dimensions of negative thinking in relation to different types of hypothetical events. Results of a study investigating the CQ's association with depression and its capacity to detect residual cognitive vulnerability following an episode of depression are reported.

The effects on depressive thinking and depressed mood of a brief, standardized distraction procedure were examined. In low endogenous patients (scoring 3 or less on the Newcastle Diagnosis Scale (NDS)), distraction significantly reduced the frequency of depressing thoughts. Consistent with Beck's cognitive model of depression, these patients were significantly less depressed after distraction than after a control procedure. In high endogenous patients (scoring 4 or more on the NDS), distraction produced less marked reductions in frequency of depressing thoughts, and no significant change in depressed mood. It is suggested that the relationship between negative thinking and depressed mood differs in the two patient groups.

Cognitive therapy for depression is a psychological treatment designed to train patients to identify and correct the negative depressive thinking which, it has been hypothesised, contributes to the maintenance of depression. General practice patients meeting Research Diagnostic Criteria for primary major depressive disorder were randomly allocated either to continue with the treatment they would normally receive (which in the majority of cases included antidepressant medication) or to receive, in addition, sessions of cognitive therapy. At completion of treatment, patients receiving cognitive therapy were significantly less depressed than the comparison group, both on blind ratings of symptom severity made by psychiatric assessors and on a self-report measure of severity of depression. At three-month follow-up cognitive therapy patients no longer differed from patients receiving treatment-as-usual, but this was mainly as a result of continuing improvement in the comparison group.